• SPX
  • $5,967.12
  • 0.31 %
  • $18.41
  • DJI
  • $44,179.24
  • 0.7 %
  • $308.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,000.30
  • 0.15 %
  • $27.88
Lexaria Bioscience Corp. (LEXXW) Stock Price, News & Analysis

Lexaria Bioscience Corp. (LEXXW) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.68

-$0.02

(-2.86%)

Day's range
$0.68
Day's range
$0.68
50-day range
$0.5044
Day's range
$1.34
  • Country: US
  • ISIN: US52886N1173
52 wk range
$0.68
Day's range
$0.68
  • CEO: Mr. Christopher A. Bunka
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 69.82
  • Piotroski Score 4.00
  • Grade N/A
  • Symbol (LEXXW)
  • Company Lexaria Bioscience Corp.
  • Price $0.68
  • Changes Percentage (-2.86%)
  • Change -$0.02
  • Day Low $0.68
  • Day High $0.68
  • Year High $0.68

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 05/30/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.00
  • Trailing P/E Ratio N/A
  • Forward P/E Ratio N/A
  • P/E Growth N/A
  • Net Income $-6,664,899

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Lexaria Bioscience Corp. Frequently Asked Questions

  • What is the Lexaria Bioscience Corp. stock price today?

    Today's price of Lexaria Bioscience Corp. is $0.68 — it has decreased by -2.86% in the past 24 hours. Watch Lexaria Bioscience Corp. stock price performance more closely on the chart.

  • Does Lexaria Bioscience Corp. release reports?

    Yes, you can track Lexaria Bioscience Corp.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Lexaria Bioscience Corp. stock forecast?

    Watch the Lexaria Bioscience Corp. chart and read a more detailed Lexaria Bioscience Corp. stock forecast to see what analysts suggest you do with its shares.

  • What is Lexaria Bioscience Corp. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Lexaria Bioscience Corp. stock ticker.

  • How to buy Lexaria Bioscience Corp. stocks?

    Like other stocks, LEXXW shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Lexaria Bioscience Corp.'s EBITDA?

    Lexaria Bioscience Corp. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Lexaria Bioscience Corp.’s financial statements.

  • What is the Lexaria Bioscience Corp.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -29.4635866106, which equates to approximately -2,946.36%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Lexaria Bioscience Corp. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Lexaria Bioscience Corp.'s financials relevant news, and technical analysis. Lexaria Bioscience Corp.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Lexaria Bioscience Corp. stock currently indicates a “sell” signal. For more insights, review Lexaria Bioscience Corp.’s technical analysis.

  • A revenue figure for Lexaria Bioscience Corp. for its last quarter?

    Lexaria Bioscience Corp. published it's last quarterly revenues at $84,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.